IXICO plc
("IXICO" or the "Company")
Investor presentation
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that a recording of the online Company presentation, delivered by Giulio Cerroni, Chief Executive Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25 August, surrounding the Company's recent trading update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting.
Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link, which will take you to the recording of the presentation and the Q&A: https://www.investormeetcompany.com/ixico-plc/register-investor
No new price-sensitive information is disclosed as part of the presentation.
For further information please contact:
IXICO plc |
+44 (0)20 3763 7498 |
|||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
|||
|
|
|||
Cenkos Securities PLC (Nominated adviser and sole broker) |
+44 (0)20 7397 8900 |
|||
Giles Balleny / Max Gould (Corporate Finance) |
|
|||
Michael F Johnson / Russell Kerr (Sales) |
|
|||
|
|
|||
Walbrook PR Ltd |
Tel: 020 7933 8780 or IXICO@walbrookpr.com
|
|||
Paul McManus / Lianne Cawthorne / |
Mob: 07980 541 893 / 07584 391 303 / |
|||
Alice Woodings |
07407 804 654 |
|||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com